1.Expert consensus on the medication catalog for drug-induced liver injury and rational drug use
Jianchun LI ; Di CHEN ; Pengfei JIN ; Gerontology NATIONAL ; Association GERIATRIC ; Research PHARMACY ; Society PHARMACY ; Association GERIATRIC
China Pharmacy 2026;37(3):273-280
OBJECTIVE To systematically sort out the drugs causing drug-induced liver injury (DILI) and their relevant information, and to develop the Expert consensus on the medication catalog for drug-induced liver injury and rational drug use (hereinafter referred to as the Consensus), so as to provide a reference for rational clinical use. METHODS Systematic searches were conducted across various literature databases, guideline retrieval websites and professional liver injury websites. Drugs identified as causing DILI from the included literature and online resources were extracted and assigned scores based on source credibility: three points for LiverTox A-class drugs and two points for B-class drugs; two points for drugs from Hepatox and guidelines; and one point for drugs from consensus and related literature sources. Drugs classified as LiverTox category A/B or with total scores ≥4 were included in the preliminary list of DILI-causing drugs. Opinions were collected and integrated from a multidisciplinary expert panel comprising 45 medical and pharmaceutical experts from 27 provinces across China through three rounds of the Delphi method (including questionnaires and discussion sessions), and after revision, the final version of Consensus was formed. RESULTS & CONCLUSIONS This Consensus included 12 traditional Chinese medicines (TCMs) such as Polygoni Multiflori Radix and Ephedrae Herba, 151 Western medicines including amiodarone and atorvastatin, along with rational use information. For TCM, eight rational use information were included: evidence-based score, liver injury classification based on pathogenesis, liver injury classification based on biochemical abnormality pattern, clinical phenotype, laboratory examination manifestations, latency period, recovery time, and management strategies. For Western medicines, six additional items were included based on the TCM, namely liver function monitoring, discontinuation, contraindications, cautions, dose adjustments, and risk factors, totaling 14 items. This Consensus systematically compiles DILI drugs and their rational use information, which will support clinicians in enhancing the prevention, identification, and management of DILI, reducing the incidence of liver injury, and ensuring patient medication safety and efficacy.
2.Chinese expert consensus on ultrasound-guided percutaneous lung needle biopsy (2025 edition)
Society of Ultrasound in Medicine CHINESE ; Physicians Branch of Chinese Medical Doctor Association INTERVENTIONAL ; Of Minimally Invasive Therapy in Oncology, China Anti-Cancer Association SOCIETY ; Branch of Chinese Anti-Tuberculosis Association ULTRASOUND ; Control and Prevention Branch of China International Exchange and Promotive Association for Medical and Health Care TUBERCULOSIS ; Equipment Technology Branch of China Association of Medical Equipment ULTRASOUND ; Sub-Committee of Tuberculosis Branch of Chinese Medical Association ULTRASOUND ; Branch of Shanghai Medical Association ULTRASOUND ; Engineering Research Center of Ultrasound in Diagnosis and Treatment SHANGHAI ; Institute of Medical Imaging SHANGHAI
Chinese Journal of Clinical Medicine 2026;33(2):346-368
Ultrasound-guided percutaneous lung needle biopsy (US-PLNB) is a pivotal diagnostic technique for subpleural pulmonary lesions, offering significant advantages such as real-time imaging, absence of ionizing radiation, and high operational flexibility. To standardize its clinical application and enhance both procedural safety and diagnostic accuracy, a multidisciplinary panel of experts was convened by eleven authoritative Chinese academic societies, including Chinese Society of Ultrasound in Medicine. Based on the latest domestic and international evidence-based medicine, this panel developed Chinese expert consensus on ultrasound-guided percutaneous lung needle biopsy (2025 edition). This consensus systematically elaborates on the indications and contraindications, preprocedural assessment and preparation, intraoperative techniques, complication prevention and management, and post-procedural care for US-PLNB. Furthermore, it puts forward 18 specific evidence-based recommendations. The primary aim of this consensus is to provide radiologists and clinicians with standardized operational guidance, promote the standardized application of US-PLNB, and ultimately improve patient care for individuals with pulmonary diseases.
3.Guideline for the diagnosis and comprehensive treatment of colorectal cancer liver metastases (2025 edition)
College of Surgeons, Chinese Medical Doctor Association CHINESE ; Surgery Group, Chinese Society of Surgery, Chinese Medical Association GASTROINTESTINAL ; Surgery Group, Chinese Society of Surgery, Chinese Medical Association COLORECTAL ; Cancer Professional Committee, Chinese Anti-Cancer Association COLORECTAL ; Cancer Professional Committee, Chinese Medical Doctor Association COLORECTAL ; Cancer Expert Committee, Chinese Society of Clinical Oncology COLORECTAL ; Surgeons Committee, Chinese Congress of Surgeons, Chinese Medical Doctor Association COLORECTAL ; Metastasis Committee, Anorectal Branch of Chinese Medical Doctor Association TUMOR ; Of Colorectal Oncology, Chinese Society of Oncology, Chinese Medical Association SECTION ; Tumor Therapeutics Branch, China International Exchange and Promotive Association for Medical and Health Care METASTATIC ; Disease Branch, China International Exchange and Promotive Association for Medical and Health Care COLORECTAL
Chinese Journal of Clinical Medicine 2026;33(1):160-190
The liver is the primary target organ for hematogenous metastasis of colorectal cancer, and colorectal cancer liver metastasis is one of the key and challenging aspects in its treatment. In order to improve the diagnosis and comprehensive treatment of colorectal cancer liver metastasis in China, the guideline development group has summarized advanced experiences and the latest achievements from both domestic and international sources, and has once again revised and updated the Guideline for the diagnosis and comprehensive treatment of colorectal cancer liver metastases (2025 edition) to continuously provide guidance and reference for clinical practice in this field in China.
4.Expert consensus on service capability and quality control of student vision health management institutions
Lihua YANG ; Xi WU ; Dongru LIU
Journal of Public Health and Preventive Medicine 2026;37(3):185-188
Objective To provide scientific and normative guidance for capacity building and quality control standards for vision health management service institutions, thereby promoting the standardization and professional development of the industry, enhancing service quality, and improving the effectiveness of myopia prevention and control. Methods A multidisciplinary expert panel organized by Society of Vision Health Management, Chinese Health Association, based on standards such as the "Technical Specifications for Vision Health Management Services for Primary and Secondary School Students" (T/CHAA 008-2019) and combined with field research data, revised and formed this consensus through multiple rounds of meetings and discussions. Results This consensus clarifies the positioning of service institutions, core service capability requirements (covering basic configuration, personnel and equipment, service processes, scope, and competency levels), and quality control points throughout the service process. It establishes an evaluation framework centered on "foundational support - service implementation - management effectiveness - outcome output." Conclusion This consensus provides systematic guidance for the standardized construction, capacity evaluation, and quality control of vision health management service institutions, which is of great significance for safeguarding the vision health of children and adolescents.
5.Expert consensus on artificial intelligence methods based on multimodal data for predicting adverse drug reactions of antineoplastics
Antineoplastics WRITING ; Association CLINICAL ; Association MEDICATION ; Association HEMATOLOGY ; Association GERIATRIC
China Pharmacy 2026;37(14):1797-1804
OBJECTIVE To provide guidance on the scientific and standardized application of artificial intelligence (AI) and multimodal fusion techniques in constructing predictive models for adverse drug reactions (ADR) of antineoplastics, thereby enhancing the safety of antineoplastic therapy. METHODS Jointly initiated by the Clinical Pharmacy and Translational Pharmacy Society of the Liaoning Provincial Life Sciences Association and other professional societies, and organized by the Fourth Affiliated Hospital of China Medical University, the writing group conducted a comprehensive search of domestic and international databases using keywords such as “multimodal data” “artificial intelligence” “adverse drug reactions”“antineoplastics” and “models” to collect guidelines, expert consensuses, and relevant guidance literature. Based on this search, and combined with China’s practical experience in applying AI to oncology pharmaceutical care, a consensus framework and preliminary recommendations were drafted. Following evaluation and discussion by an external expert panel, the writing group incorporated the assessment results and formulated recommendations based on those endorsed by 90% or more of the experts. RESULTS &CONCLUSIONS After multiple rounds of review, discussion and revision, this consensus outlines the process for constructing an ADR prediction model of antineoplastics, encompassing “defining research objectives-data preparation-selection of algorithmic frameworks-design of multimodal data fusion strategies-model training and validation-interpretability analysis-clinical deployment-publication of results”. It also formulates 18 recommendations regarding core aspects such as data preparation, algorithm framwork selection, multimodal data fusion strategy design, model validation and interpretability analysis, and clinical deployment. These recommendations are intended for use by physicians in the field of oncology, clinical pharmacists, researchers, and AI technology developers to assist in making optimal clinical treatment decisions.
6.Expert consensus on basic public services for vision health management of primary and secondary school students
YANG Lihua , WU Xi, TAO Shuman, YAO Jun, WU Fengbo, LIU Fangli, MA Yinghua, FENG Zhanchun, SUN Renbiao, LIU Dongru, CHEN Qiusheng, CHEN Jie, YU Yizhen, ZHANG Mingchang, WU Xiaoyan, DU Yukai, LI Xiaoqing, LI Li, WU Xixi, JIN Xiaoqin, XU Ting, WU Mengjia, TANG Jia, Society of Student Vision Health Management of Chinese Health Association, Vision Health Branch of Chinese Association for Student Nutrition & ; Health Promotion
Chinese Journal of School Health 2026;47(8):1069-1074
Abstract
To clarify the service targets, service contents, and safeguard mechanisms of the basic public service program for student vision health management, the study grounded in the current status of child and adolescent myopia prevention and control in China and integrated with the practical experience and innovative practices of Wuhan National Demonstration Area for Student Vision Health Management, takes education as the main thread and schools as the base, consolidating resources from multiple stakeholders including education administrative departments, schools, families, and professional technical service institutions. Centering on four core components—vision health education, monitoring and record keeping, risk prevention and control, and dynamic management, the study constructs a multi tiered basic public service system for vision health management of primary and secondary school students. It further proposes the use of an intelligent management platform and a "three tier color coded early warning" mechanism (red, yellow, blue) to prevent and control student myopia at the source, providing schools with replicable and operable implementation pathways to enhance the level of student vision health management.
7.Clinical practice guidelines for intraoperative cell salvage in patients with malignant tumors
Changtai ZHU ; Ling LI ; Zhiqiang LI ; Xinjian WAN ; Shiyao CHEN ; Jian PAN ; Yi ZHANG ; Xiang REN ; Kun HAN ; Feng ZOU ; Aiqing WEN ; Ruiming RONG ; Rong XIA ; Baohua QIAN ; Xin MA
Chinese Journal of Blood Transfusion 2025;38(2):149-167
Intraoperative cell salvage (IOCS) has been widely applied as an important blood conservation measure in surgical operations. However, there is currently a lack of clinical practice guidelines for the implementation of IOCS in patients with malignant tumors. This report aims to provide clinicians with recommendations on the use of IOCS in patients with malignant tumors based on the review and assessment of the existed evidence. Data were derived from databases such as PubMed, Embase, the Cochrane Library and Wanfang. The guideline development team formulated recommendations based on the quality of evidence, balance of benefits and harms, patient preferences, and health economic assessments. This study constructed seven major clinical questions. The main conclusions of this guideline are as follows: 1) Compared with no perioperative allogeneic blood transfusion (NPABT), perioperative allogeneic blood transfusion (PABT) leads to a more unfavorable prognosis in cancer patients (Recommended); 2) Compared with the transfusion of allogeneic blood or no transfusion, IOCS does not lead to a more unfavorable prognosis in cancer patients (Recommended); 3) The implementation of IOCS in cancer patients is economically feasible (Recommended); 4) Leukocyte depletion filters (LDF) should be used when implementing IOCS in cancer patients (Strongly Recommended); 5) Irradiation treatment of autologous blood to be reinfused can be used when implementing IOCS in cancer patients (Recommended); 6) A careful assessment of the condition of cancer patients (meeting indications and excluding contraindications) should be conducted before implementing IOCS (Strongly Recommended); 7) Informed consent from cancer patients should be obtained when implementing IOCS, with a thorough pre-assessment of the patient's condition and the likelihood of blood loss, adherence to standardized internally audited management procedures, meeting corresponding conditions, and obtaining corresponding qualifications (Recommended). In brief, current evidence indicates that IOCS can be implemented for some malignant tumor patients who need allogeneic blood transfusion after physician full evaluation, and LDF or irradiation should be used during the implementation process.
8.Executive summary: indonesian guidelines on polycystic ovary syndrome management
Mila MAIDARTI ; Achmad Kemal HARZIF ; Amalia SHADRINA ; Nafi'atul UMMAH ; Wiryawan PERMADI ;
Obstetrics & Gynecology Science 2025;68(3):221-236
Objective:
Polycystic ovary syndrome (PCOS) is a gynecological, endocrine condition characterized by ovulatory disorders, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. PCOS has significant metabolic and reproductive implications that affect the quality of life of women. This PCOS guideline summary is based on the Indonesian Reproductive Endocrinology and Fertility Association guidelines for PCOS. This guideline is expected to guide the diagnosis and long-term management of PCOS.
Methods:
We searched scientific evidence on the Cochrane and PubMed databases using the keyword “polycystic ovary syndrome”. This evidence was reviewed by experts in the field of obstetrics and gynecology, and recommendations were made based on scientific evidence while considering patient values, costs, and resources.
Results:
A total of 127 recommendations and practice points were made regarding the diagnosis and management of PCOS. The levels of available health services and management algorithms for PCOS in Indonesia are also included.
Conclusion
The first-line treatment for managing hyperandrogenism and menstrual disorders in patients with PCOS is combined oral contraceptives. The first-line treatment for ovulation induction is letrozole, while clomiphene citrate, metformin, gonadotropins, and ovarian surgery serve as the second-line treatment. The third-line treatments included in vitro fertilization, with or without in vitro maturation.
9.Expert consensus on precision detection of intrahepatic cholangiocarcinoma (2024 edition)
, Shanghai 200032, China PATHOLOGY GROUP, CHINESE SOCIETY OF LIVER CANCER OF CHINESE ANTI-CANCER ASSOCIATION ; LIVER PATHOLOGY GROUP, CHINESE SOCIETY OF PATHOLOGY OF CHINESE ANTI-CANCER ASSOCIATION ; TUMOR PATHOLOGY COMMITTEE OF SHANGHAI ANTI-CANCER ASSOCIATION
Chinese Journal of Clinical Medicine 2025;32(1):145-160
Intrahepatic cholangiocarcinoma (ICC) is a highly heterogeneous tumor, and molecular profiling serves as the foundation for personalized treatment of ICC. Accurate detection methods are clinically significant for comprehensively screening patients suitable for targeted therapies. This consensus is based on clinical practice data from both domestic and international sources, tailored to the Chinese context, and focuses on key targets for ICC. We present 15 recommendations aimed at guiding the precision detection of ICC.
10.Validation of the OMRON automated oscillometric blood pressure monitoring device HEM 7156 using the association for the advancement of medical instrumentation/european society of hypertension/international organization for standardization (AAMI/ESH/ISO) universal standard (ISO 81060-2:2018)
Benjamin A. Balmores Jr. ; Raymond V. Oliva ; Deborah Ignacia David-Ona ; Dolores D. Bonzon ; Alejandro Bimbo F. Diaz ; Arnold Benjamin C. Mina ; Marlon T. Co ; Erick S. Mendoza ; Alberto A. Atilano ; Leilani B. Mercado-Asis ; Adriel E. Guerrero ; Lourdes Ella G. Santos
Philippine Journal of Cardiology 2025;53(2):52-57
BACKGROUND
Blood pressure (BP) is a vital sign that is essential in the management of hypertension, thus, there is a need for accurate measurement of BP. This will allow for proper diagnosis and management of hypertension preventing cardiovascular morbidity and mortality among Filipino patients.
METHODOLOGYThis validation study utilized the US Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) protocol for BP monitors. A total of eighty-five (85) participants had their BP measured using both the HEM 7156 and a validated aneroid sphygmomanometer. The same-sequential BP measurement was recommended to be used and a total of nine readings were collected per individual. The mean average of BP and standard deviation were extracted from the measurements. The AAMI/ESH/ISO recommends the use of certain criteria for individual BP readings (criterion 1) and individual participants (criterion 2). Appropriate statistical analysis was used for other demographic data.
RESULTSThe participants had an average age of 34 years, more than half were females, and not diagnosed with hypertension. Individuals who were diagnosed with hypertension had no other comorbidities and were on single pill only. The average arm circumference was 26.9 cm. Blood Pressure (BP) readings were adequate based on the protocol. Validity results showed that for criterion 1, systolic blood pressure (SBP) difference was 3.4 ± 7.4 mmHg, while diastolic blood pressure (DBP) was 2.0 ± 8.0 mmHg. The results for criterion 2 showed for SBP was 3.3 ± 5.3 mmHg, while DBP was 1.9 ± 6.6 mmHg. The results satisfied a passing grade on the validation protocol set by the AAMI/ESH/ISO.
CONCLUSIONThis study showed that OMRON HEM 7156 is validated as a BP apparatus and may be recommended for Philippine use.
Human ; Hypertension


Result Analysis
Print
Save
E-mail